BRPI0415249A - terapia de combinação para infecção por hcv - Google Patents

terapia de combinação para infecção por hcv

Info

Publication number
BRPI0415249A
BRPI0415249A BRPI0415249-2A BRPI0415249A BRPI0415249A BR PI0415249 A BRPI0415249 A BR PI0415249A BR PI0415249 A BRPI0415249 A BR PI0415249A BR PI0415249 A BRPI0415249 A BR PI0415249A
Authority
BR
Brazil
Prior art keywords
hcv infection
present
combination therapy
relates
combinations
Prior art date
Application number
BRPI0415249-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BRPI0415249A publication Critical patent/BRPI0415249A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0415249-2A 2003-10-11 2004-10-12 terapia de combinação para infecção por hcv BRPI0415249A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
PCT/US2004/033739 WO2005037274A1 (en) 2003-10-11 2004-10-12 Combination therapy for hcv infection

Publications (1)

Publication Number Publication Date
BRPI0415249A true BRPI0415249A (pt) 2006-12-12

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415249-2A BRPI0415249A (pt) 2003-10-11 2004-10-12 terapia de combinação para infecção por hcv

Country Status (17)

Country Link
US (1) US20050112093A1 (enExample)
EP (1) EP1670462A1 (enExample)
JP (1) JP2007508326A (enExample)
KR (1) KR20060120037A (enExample)
CN (1) CN1882335A (enExample)
AR (1) AR045870A1 (enExample)
AU (1) AU2004281747A1 (enExample)
BR (1) BRPI0415249A (enExample)
CA (1) CA2541857A1 (enExample)
IL (1) IL174864A0 (enExample)
MX (1) MXPA06004077A (enExample)
NO (1) NO20062104L (enExample)
PE (1) PE20050477A1 (enExample)
RU (1) RU2006115916A (enExample)
TW (1) TW200528104A (enExample)
WO (1) WO2005037274A1 (enExample)
ZA (1) ZA200602912B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
CN101903392A (zh) * 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
WO2010033443A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
JPWO2011001897A1 (ja) * 2009-06-30 2012-12-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126674A (en) * 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
BR9910505A (pt) * 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20040034206A1 (en) * 2002-05-31 2004-02-19 Schering Corporation Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors

Also Published As

Publication number Publication date
AU2004281747A1 (en) 2005-04-28
ZA200602912B (en) 2007-06-27
WO2005037274A1 (en) 2005-04-28
PE20050477A1 (es) 2005-08-24
US20050112093A1 (en) 2005-05-26
TW200528104A (en) 2005-09-01
CA2541857A1 (en) 2005-04-28
NO20062104L (no) 2006-05-10
EP1670462A1 (en) 2006-06-21
KR20060120037A (ko) 2006-11-24
CN1882335A (zh) 2006-12-20
IL174864A0 (en) 2008-04-13
JP2007508326A (ja) 2007-04-05
RU2006115916A (ru) 2007-12-10
AR045870A1 (es) 2005-11-16
MXPA06004077A (es) 2006-06-27

Similar Documents

Publication Publication Date Title
BRPI0415249A (pt) terapia de combinação para infecção por hcv
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BRPI0409125A (pt) terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR0010612A (pt) Vacinas
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
BR0115162A (pt) Tratamentos antitumorais eficazes
NO20072543L (no) Anti-cancer-behandling
BRPI0407234A (pt) Heterociclos substituìdos
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
BR0316227A (pt) IsÈmeros posicionais de peg ifn alfa 2a
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DOP2002000451A (es) Nuevas ciclohexilsulfonas (agentes terapéuticos)
BRPI0415893A (pt) métodos para tratar insÈnia em um paciente humano em necessidade do mesmo, para tratar insÈnia primária em um paciente humano adulto ou idoso em necessidade do mesmo e para melhorar o funcionamento no horário diurno em um paciente humano em necessidade do mesmo, uso do gaboxadol, e, composição farmacêutica
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
BRPI0406985A (pt) Terapia de combinação de hcv

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]